[go: up one dir, main page]

NO20074615L - Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer - Google Patents

Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer

Info

Publication number
NO20074615L
NO20074615L NO20074615A NO20074615A NO20074615L NO 20074615 L NO20074615 L NO 20074615L NO 20074615 A NO20074615 A NO 20074615A NO 20074615 A NO20074615 A NO 20074615A NO 20074615 L NO20074615 L NO 20074615L
Authority
NO
Norway
Prior art keywords
dihydrotienopyrimidines
treatment
inflammatory diseases
diseases
racemates
Prior art date
Application number
NO20074615A
Other languages
English (en)
Inventor
Christoph Hoenke
Birgit Jung
Pascale Pouzet
Domnic Martyres
Peter Nickolaus
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20074615L publication Critical patent/NO20074615L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Oppfinnelsen angår nye dihydrotienopyrimidiner med formel 1 og de farmakologisk akseptable salter, diastereomerer, enantiomerer, racemater, hydrater eller solvater derav, 1 som er egnet for behandling av respiratoriske eller gastrointestinale plager eller sykdommer, inflammatoriske sykdommer i ledd, hud eller øyne, sykdommer i det perifere eller sentrale nervesystem eller kreft, så vel som farmasøytiske preparater som inneholder disse forbindelsene.
NO20074615A 2006-04-19 2007-09-12 Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer NO20074615L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005019201A DE102005019201A1 (de) 2006-04-19 2006-04-19 Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
PCT/EP2006/061680 WO2006111549A1 (de) 2005-04-21 2006-04-19 Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen

Publications (1)

Publication Number Publication Date
NO20074615L true NO20074615L (no) 2007-11-19

Family

ID=36678631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074615A NO20074615L (no) 2006-04-19 2007-09-12 Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer

Country Status (28)

Country Link
US (3) US7511045B2 (no)
EP (2) EP1874781B9 (no)
JP (1) JP5021624B2 (no)
KR (1) KR101335964B1 (no)
CN (1) CN101163706A (no)
AR (1) AR053235A1 (no)
AT (1) ATE434620T1 (no)
AU (1) AU2006237354B2 (no)
BR (1) BRPI0608387A2 (no)
CA (1) CA2605161A1 (no)
CY (1) CY1109348T1 (no)
DE (2) DE502006004066D1 (no)
DK (1) DK1874781T3 (no)
EA (1) EA013108B1 (no)
ES (1) ES2328400T3 (no)
HR (1) HRP20090395T1 (no)
IL (1) IL186749A (no)
MX (1) MX2007012313A (no)
NO (1) NO20074615L (no)
NZ (1) NZ563488A (no)
PL (1) PL1874781T3 (no)
PT (1) PT1874781E (no)
RS (1) RS51163B (no)
SI (1) SI1874781T1 (no)
TW (1) TWI380984B (no)
UA (1) UA93872C2 (no)
WO (1) WO2006111549A1 (no)
ZA (1) ZA200707591B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111549A1 (de) 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ES2462240T3 (es) * 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
EP1847543A1 (de) * 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
PL2205608T3 (pl) * 2007-10-18 2013-09-30 Boehringer Ingelheim Int Sposób otrzymywania dihydrotieno[3,2-d]pirymidyn i związków pośrednich stosowanych w tym sposobie
US20110028441A1 (en) * 2007-10-19 2011-02-03 Boehringer Ingelheim International Gmbh Novel phenyl-substituted piperazino-dihydrothienopyrimidines
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
EP2205609B1 (de) * 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
US8754073B2 (en) * 2007-10-19 2014-06-17 Boehringer Ingelheim International Gmbh Substituted piperazino-dihydrothienopyrimidines
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
ES2428716T3 (es) 2008-02-22 2013-11-11 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide
CN102026984B (zh) * 2008-05-13 2013-12-25 贝林格尔.英格海姆国际有限公司 二氢噻吩并[3,2-d]嘧啶二酚及类似嘧啶二酚的合成
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
US8637678B2 (en) * 2008-12-24 2014-01-28 Syngenta Limited Methods for the preparation of aryl amides
EP2400961B1 (de) * 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
CN102421767B (zh) * 2009-03-10 2014-06-18 武田药品工业株式会社 苯并呋喃衍生物
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20140113877A1 (en) * 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
WO2013019966A1 (en) * 2011-08-04 2013-02-07 Allergan, Inc. Aromatic bycyclic derivatives as cxcr4 receptor modulators
US9206195B2 (en) 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
GB201203266D0 (en) * 2012-02-24 2012-04-11 Randox Lab Ltd Assay for the detection of the phenylpiperazine family
WO2014105958A2 (en) 2012-12-26 2014-07-03 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
WO2014117947A1 (en) * 2013-02-04 2014-08-07 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
RU2668073C2 (ru) 2013-03-14 2018-09-26 Дарт Нейросайенс (Кайман) Лтд. Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN103893183B (zh) * 2014-03-12 2016-02-10 中山大学 1-（2-氯苯基）-4-{噻吩并[3,2-d]嘧啶-4-基}哌嗪化合物在制备抗HIV-1病毒药物中应用
CA2969839A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
CN111587112B (zh) * 2017-09-01 2023-10-10 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
CN111108109A (zh) 2017-09-20 2020-05-05 利奥制药有限公司 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
EP3700529B1 (en) 2017-10-23 2025-07-09 Boehringer Ingelheim International GmbH New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EP3724196B9 (en) 2017-12-15 2023-03-22 UNION therapeutics A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
ES2968822T3 (es) 2017-12-15 2024-05-14 Union Therapeutics As Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
ES2968824T3 (es) 2017-12-15 2024-05-14 Union Therapeutics As Tetrahidropirano dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
CA3234847A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
US20230190754A1 (en) 2021-12-09 2023-06-22 Boehringer Ingelheim International Gmbh Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
KR20250046278A (ko) * 2022-08-09 2025-04-02 시젱 하이스코 파마수티칼 씨오., 엘티디. Pde4b 억제제 및 이의 용도
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
WO2024067660A1 (zh) 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
EP4678644A1 (en) 2023-04-13 2026-01-14 Shanghai Yidi Biotechnology Co., Ltd. Substituted dihydrothienopyrimidine compound, preparation method therefor, and use thereof
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
WO2025067168A1 (zh) * 2023-09-25 2025-04-03 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
CN120398908A (zh) * 2024-02-01 2025-08-01 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025162289A2 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂的晶型及其在医药上的用途
WO2025162431A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂化合物的口服药物组合物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (no) * 1963-06-17
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (no) 1965-03-31
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1940572A1 (de) * 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) * 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (no) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
RO62428A (fr) * 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
DE2121950A1 (en) * 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4265738A (en) * 1979-10-25 1981-05-05 Goncharov Evgeny S Cleaning and/or grading machine for free-flowing materials
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
US6339089B2 (en) * 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
IL155335A0 (en) 2000-10-12 2003-11-23 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
DE10064994A1 (de) * 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
EP1465900B1 (en) * 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
JP4015176B2 (ja) * 2003-04-29 2007-11-28 ファイザー・インク 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) * 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
WO2006111549A1 (de) 2005-04-21 2006-10-26 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
IL186749A0 (en) 2008-02-09
PL1874781T3 (pl) 2009-12-31
AR053235A1 (es) 2007-04-25
MX2007012313A (es) 2007-11-21
IL186749A (en) 2014-08-31
US7511045B2 (en) 2009-03-31
US20070259846A1 (en) 2007-11-08
EP1874781B9 (de) 2010-09-08
ES2328400T3 (es) 2009-11-12
NZ563488A (en) 2010-04-30
US8354531B2 (en) 2013-01-15
TWI380984B (zh) 2013-01-01
ATE434620T1 (de) 2009-07-15
BRPI0608387A2 (pt) 2009-12-29
AU2006237354B2 (en) 2012-03-01
US7723341B2 (en) 2010-05-25
KR20080004621A (ko) 2008-01-09
EA013108B1 (ru) 2010-02-26
JP2008536890A (ja) 2008-09-11
SI1874781T1 (sl) 2009-12-31
EA200702200A1 (ru) 2008-04-28
HRP20090395T1 (hr) 2009-08-31
EP2060575A1 (de) 2009-05-20
AU2006237354A1 (en) 2006-10-26
CY1109348T1 (el) 2014-07-02
DK1874781T3 (da) 2009-11-02
EP1874781B1 (de) 2009-06-24
WO2006111549A1 (de) 2006-10-26
CN101163706A (zh) 2008-04-16
US20090186875A1 (en) 2009-07-23
DE102005019201A1 (de) 2006-11-02
US20100197656A1 (en) 2010-08-05
ZA200707591B (en) 2009-08-26
EP1874781A1 (de) 2008-01-09
DE502006004066D1 (de) 2009-08-06
CA2605161A1 (en) 2006-10-26
UA93872C2 (ru) 2011-03-25
JP5021624B2 (ja) 2012-09-12
RS51163B (sr) 2010-10-31
KR101335964B1 (ko) 2013-12-04
PT1874781E (pt) 2009-07-27

Similar Documents

Publication Publication Date Title
NO20074615L (no) Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer
NO20083710L (no) Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20045589L (no) Nye forbindelser
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20084328L (no) Nye forbindelser
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20092033L (no) Nye forbindelser
SE0402735D0 (sv) Novel compounds
NO20081844L (no) Terapeutiske forbindelser
NO20085100L (no) Nye forbindelser
NO20082445L (no) Neuropeptid-2 reseptor-agonister
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
MX2009004908A (es) Compuestos quimicos.
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
WO2007135026A3 (de) Substituierte pteridine als therapeutika
MX2009006947A (es) Derivados de pirimidona 6-heterociclica 2-sustituida.
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
NO20081082L (no) Nye piperidinderivater som kjemokinreseptorformulatorer som er nyttige for behandling av respiratoriske sykdommer
NO20083790L (no) Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application